NEAT1 and thyroid gland carcinoma: The investigation showed that NEAT1 and neuro-oncological ventral antigen 1 (NOVA1) are targets of miR-592, and the knockdown of NEAT1 and NOVA1 effectively abolish the promotion effects of miR-592 downregulation in thyroid cancer cells, suggesting a vital role of NEAT1/miR-592/NOVA1 axis in thyroid cancer progression 129.